Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees118
Next Earnings Date8/1/2019 (Estimated)
OptionableNot Optionable
Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions
What is Kaleido Biosciences' stock symbol?
Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."
How were Kaleido Biosciences' earnings last quarter?
Kaleido Biosciences Inc (NASDAQ:KLDO) released its quarterly earnings data on Thursday, May, 2nd. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.89. View Kaleido Biosciences' Earnings History.
When is Kaleido Biosciences' next earnings date?
What price target have analysts set for KLDO?
5 Wall Street analysts have issued 12-month price objectives for Kaleido Biosciences' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Kaleido Biosciences' share price to reach $17.70 in the next twelve months. This suggests a possible upside of 24.1% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.
What is the consensus analysts' recommendation for Kaleido Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.
Has Kaleido Biosciences been receiving favorable news coverage?
News headlines about KLDO stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kaleido Biosciences earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Kaleido Biosciences.
Who are some of Kaleido Biosciences' key competitors?
Some companies that are related to Kaleido Biosciences include Tricida (TCDA), Enanta Pharmaceuticals (ENTA), BioTelemetry (BEAT), ProMetic Life Sciences (PLI), Genus (GNS), Audentes Therapeutics (BOLD), Zogenix (ZGNX), Supernus Pharmaceuticals (SUPN), Shockwave Medical (SWAV), Atrion (ATRI), Ironwood Pharmaceuticals (IRWD), Primary Health Care (PRY), Nanosonics (NAN), Clinigen Group (CLIGF) and Magellan Health (MGLN).
What other stocks do shareholders of Kaleido Biosciences own?
Who are Kaleido Biosciences' key executives?
Kaleido Biosciences' management team includes the folowing people:
- Mr. Michael W. Bonney, Exec. Chair (Age 61)
- Ms. Alison Lawton, CEO, Pres & Director (Age 58)
- Dr. Noubar B. Afeyan Ph.D., Co-Founder & Director (Age 56)
- Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 38)
- Mr. Joshua T. Brumm, COO & CFO (Age 41)
When did Kaleido Biosciences IPO?
(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.
When does the company's lock-up period expire?
Kaleido Biosciences' lock-up period expires on Tuesday, August 27th. Kaleido Biosciences had issued 5,000,000 shares in its initial public offering on February 28th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
Who are Kaleido Biosciences' major shareholders?
Kaleido Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (6.07%), Baillie Gifford & Co. (1.48%), Victory Capital Management Inc. (0.32%), Dean Capital Investments Management LLC (0.14%) and Barometer Capital Management Inc. (0.10%). Company insiders that own Kaleido Biosciences stock include Michael W Bonney and Ventures Fund V LP Flagship. View Institutional Ownership Trends for Kaleido Biosciences.
Which major investors are buying Kaleido Biosciences stock?
KLDO stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Baillie Gifford & Co., Victory Capital Management Inc., Dean Capital Investments Management LLC and Barometer Capital Management Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Michael W Bonney and Ventures Fund V LP Flagship. View Insider Buying and Selling for Kaleido Biosciences.
How do I buy shares of Kaleido Biosciences?
Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kaleido Biosciences' stock price today?
One share of KLDO stock can currently be purchased for approximately $14.26.
How big of a company is Kaleido Biosciences?
MarketBeat Community Rating for Kaleido Biosciences (NASDAQ KLDO)
MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote "Outperform" if you believe KLDO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days.
